DeepMorph-Guided MDRS

for bioequivalence, stability,

and contamination control.

Audit-Ready Particle Evidence

At SizeID.bio, we make the smallest differences visible – from OINDP bioequivalence to parenteral stability and particle forensics.

Accelerate bioequivalence and CMC decisions with DeepMorph-guided MDRS: high-throughput, particle-level Raman plus imaging AI to generate statistically robust, ingredient-specific particle evidence. Your deliverables are audit-ready and aligned with your GMP expectations.

nasal spray particles on a surface individually identified and measured by means of morphology directed raman spectroscopy
Single API particle with its fluticasone Raman spectrum acquired at 1-second exposure, showing excellent signal-to-noise ratio (SNR).

Why Choose SizeID.bio?

Why Choose SizeID.bio?

Single 1.7 µm API Particle in a Nasal Spray Suspension (1s Raman).

Limitations in the market

At SizeID.bio, we quantify what others miss: sub-micron particles with AI-directed Raman, built for regulatory decisions.

SizeID.bio advantage

Your Profit:

  • For bioequivalence, you need statistical power and drug-specific discrimination.

  • For parenteral stability, you need to track changes over time | proteinaceous vs. silicone oil vs. extrinsic species.

  • For contamination control, you need to identify the source, link it to your process, and implement effective CAPA.

With SizeID.bio, you get the depth when you need it | and the precision when it matters.